BAY94-9027

BIOLOGICAL3 trials

Sponsors

Bayer

Conditions

Hemophilia A

Phase 2

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

CompletedNCT01580293

BayerHemophilia A

Start: 2012-04-23End: 2019-11-21Updated: 2023-11-07

Phase 3

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

CompletedNCT01775618

BayerHemophilia A

Start: 2013-05-29End: 2020-02-19Updated: 2020-08-21

Unknown Phase

Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A

CompletedNCT02971930

BayerHemophilia A

Start: 2017-06-20End: 2017-12-15Updated: 2018-02-01

Related Papers

Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study.

2026-01-04

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.

2024-08-202 citations

A post hoc analysis of <scp>PROTECT VIII</scp> kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia <scp>A</scp>

European Journal Of Haematology2024-01-091 citations

Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective.

2022-04-0413 citations

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study

Blood2021-11-05

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

Haemophilia2021-05-037 citations

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A

Haemophilia2021-03-1611 citations

BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study

Blood2020-11-042 citations

Improved Bleeding Outcomes in Patients Who Switched From Sucrose-Formulated rFVIII to BAY 94-9027 Prophylaxis in PROTECT VIII

Blood2020-11-04

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

Haemophilia2020-06-239 citations

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

Blood2019-11-134 citations

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Blood2019-11-132 citations

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Blood2019-11-131 citations

Prophylaxis with Extended Dosing of BAY94-9027 Decreases Overall and Joint Bleeding Rates with Consistent Consumption for Over 4 Years of Treatment

Hämostaseologie2019-02-012 citations

Site-Directed Pegylation of BDD FVIII (BAY 94-9027) Does Not Alter the Ability of the Molecule to Generate Thrombin, Activate Factor X or Become Inactivated By Activated Protein C

Blood2014-12-06